(Total Views: 1294)
Posted On: 05/25/2017 12:22:56 PM
Post# of 1460
Merck licensing deal, turning away from amyloid theory, now going after tau.
http://www.fiercebiotech.com/biotech/months-a...UifQ%3D%3D
It's beyond me why they don't look at AVXL and NTRP. They wouldn't have to pay very much for one of these companies to gleefully leap into a joint venture.
http://www.fiercebiotech.com/biotech/months-a...UifQ%3D%3D
Quote:
Merck has in fact turned away from amyloid, which is believed to cause sticky plaques to build up in the brain, to tau. This tau theory associates the onset of the disease to fibrillary tangles called tau protein. Neurofibrillary tangles group in an insoluble form in neurons, affecting normal neuronal functions.
It's beyond me why they don't look at AVXL and NTRP. They wouldn't have to pay very much for one of these companies to gleefully leap into a joint venture.
(2)
(0)
